Evaluation of the clinical therapeutic effect of gosatuzumab/Todavir

Gosatuzumab/Trodelvy (Trodelvy) is an antibody-drug conjugate (ADC) that has attracted widespread attention in the field of tumor treatment in recent years. It combines a monoclonal antibody against Trop-2 protein with the powerful chemotherapy drug irinotecan derivative SN-38, so that the drug can be precisely released at the site where Trop-2 protein is expressed on the surface of cancer cells, thereby improving the anti-cancer effect and reducing systemic side effects. In clinical practice in many countries, gosatuzumab has been used to treat some refractory tumors after failure of standard treatments, especially in high-risk patient groups such as metastatic triple-negative breast cancer (mTNBC) and advanced urothelial cancer (mUC). It has shown positive effects in delaying disease progression and improving quality of life.

The advantage of gosatuzumab lies in its targeted mechanism of action, which is particularly suitable for patients who have poor response to traditional chemotherapy or endocrine therapy. Compared with traditional chemotherapy, the drug has demonstrated higher tumor response rates and longer disease control times in specific indications. Its anti-cancer effect is not only reflected in the rapid inhibition of tumor growth, but may also increase the chance of response to subsequent treatments by affecting the microenvironment of cancer cells. Therefore, it is often regarded as a "turning point" drug that can be considered after the failure of conventional treatment options, especially for tumor subtypes that are resistant to treatment and have no obvious targets.

In actual use, the adverse reactions of gosatuzumab are similar to other ADC drugs, with the most common side effects including neutropenia, diarrhea, fatigue and nausea. These side effects are controllable in clinical management, but require close monitoring and timely adjustment of dose or supportive treatment. In some patients, the use of gosatuzumab can significantly improve the symptom burden, such as reducing tumor-related pain and improving dyspnea, etc., thus having a positive impact on improving the patient's quality of life. In addition, in real-world data, some patients who were completely refractory to other treatments achieved objective responses after using gosatuzumab, which enhanced confidence in its clinical application.

Reference materials:https://www.trodelvy.com/